

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT4273955

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
MICKAËL CHAUSSON	01/23/2017
RENAUD LECLER	01/23/2017
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	KIOMED PHARMA
<b>Street Address:</b>	RUE HAUTE CLAIRE 4
<b>City:</b>	HERSTAL
<b>State/Country:</b>	BELGIUM
<b>Postal Code:</b>	4040
<b>PROPERTY NUMBERS Total: 2</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	15420462
<b>PCT Number:</b>	EP2015067754
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(314)667-3633
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	314-552-6000
<b>Email:</b>	ipdocket@thompsoncoburn.com
<b>Correspondent Name:</b>	THOMPSON COBURN LLP/WILLIAM A. HOLTZ
<b>Address Line 1:</b>	ONE US BANK PLAZA
<b>Address Line 4:</b>	ST. LOUIS, MISSOURI 63101
<b>ATTORNEY DOCKET NUMBER:</b>	51585-163659
<b>NAME OF SUBMITTER:</b>	WILLIAM HOLTZ
<b>SIGNATURE:</b>	/WILLIAM A. HOLTZ/
<b>DATE SIGNED:</b>	02/14/2017
<b>Total Attachments: 2</b>	
source=Combined_declaration_assignment1#page1.tif	
source=Combined_declaration_assignment1#page2.tif	

**ASSIGNMENT AND DECLARATION UNDER 37 C.F.R. § 1.63**  
**(For Use with Signed Application Data Sheet)**

**Title of Invention:** Thermogelling composition

**Attorney Docket No.:**

This assignment and declaration are directed to (check one):

- ☐ the attached application;  
☐ the application identified by the title of invention given above and claiming priority of the patent application(s)

Country	Date	Application No.

- ☒ United States Application or PCT International Application No. PCT/EP2015/067754, filed on July 31, 2015

**ASSIGNMENT**

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, as a below-named inventor I have sold and assigned, and hereby sell and assign, to:

**Name of Assignee:** KiOmed Pharma

**Address of Assignee:** Rue Haute Claire 4 HERSTAL, 4040 BELGIUM

(hereinafter ASSIGNEE) all right, title, and interest in and to the above-identified invention and United States patent application, including : (i) any and all divisions or continuations thereof, and in and to any and all Letters Patent of the United States that may issue on any such application or for said invention, including any and all reissues or extensions thereof, to be held and enjoyed by said ASSIGNEE, its successors, or assigns to the full end of the term or terms for which any and all such Letters Patent may be granted; (ii) all applications for patents, utility models, and designs which may hereafter be filed for said invention in any country or countries foreign to the United States, together with the right to file such applications and the right to claim for the same the priority rights derived from said United States application under the Patent Laws of the United States, the International Convention for the Protection of Industrial Property, or any other international agreement or the domestic laws of the country in which any such application is filed, as may be applicable, to be held and enjoyed by said ASSIGNEE, its successors, or assigns to the full end of the term or terms for which any and all such patents, utility models, designs or other rights may be granted; and (iii) all forms of industrial property protection, including, without limitation, patents, utility models, inventors' certificates and designs which may be granted for said invention in any country or countries foreign to the United States and all extensions, renewals and reissues thereof, to be held and enjoyed by said ASSIGNEE, its successors, or assigns to the full end of the term or terms for which any and all such patents, utility models, designs or other rights may be granted.

I hereby authorize and request the Director of the U.S. Patent and Trademark Office to issue any and all such Letters Patent to said ASSIGNEE, its successors, or assigns in accordance herewith.

I warrant and covenant that I have the right to sell and assign the interests herein sold and assigned and that I have not executed and will not execute any document or instrument in conflict herewith.

I further covenant and agree that I will communicate to said ASSIGNEE, its successors, legal representatives, or assigns all information known to me relating to said invention or patent application and that I will execute and deliver any papers, make all rightful oaths, testify in any legal proceedings, and perform all other lawful acts necessary or desirable by said ASSIGNEE, its successors, legal representatives, or assigns to perfect title to said invention, to said application including divisions and continuations thereof and to any and all Letters Patent that may be granted therefor or thereon, including reissues or extensions, in said ASSIGNEE, its successors, or assigns, or to assist said ASSIGNEE, its successors, legal representatives, or assigns in obtaining, reissuing, or enforcing Letters Patent of the

**ASSIGNMENT AND DECLARATION UNDER 37 C.F.R. § 1.63**  
**(For Use with Signed Application Data Sheet)**

United States and any and all patents, utility models, designs or other rights that may be granted in the United States or of any country or countries foreign to the United States, for said invention.


**DECLARATION**

As a below-named inventor, I hereby declare that:

The above-identified application was made or authorized to be made by me.


I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. § 1001 by fine or imprisonment of not more than five (5) years, or both.

Signature: 

Inventor: CHAUSSON Mickaël

Date: January 23, 2017

Signature: 

Inventor: LECLERC Renaud

Date: January 23, 2017